Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Reply: Beneficial effect of interleukin-2-based immunomodulation in Alzheimer-like pathology.

Alves S, Churlaud G, Klatzmann D, Cartier N.

Brain. 2017 Jul 1;140(7):e40. doi: 10.1093/brain/awx109. No abstract available.

PMID:
28498902
2.

Beneficial effect of interleukin-2-based immunomodulation in Alzheimer-like pathology.

Dansokho C, Aucouturier P, Dorothée G.

Brain. 2017 Jul 1;140(7):e39. doi: 10.1093/brain/awx108. No abstract available.

PMID:
28498909
3.

Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice.

Alves S, Churlaud G, Audrain M, Michaelsen-Preusse K, Fol R, Souchet B, Braudeau J, Korte M, Klatzmann D, Cartier N.

Brain. 2017 Mar 1;140(3):826-842. doi: 10.1093/brain/aww330.

PMID:
28003243
4.

Long-term immunomodulatory effect of amniotic stem cells in an Alzheimer's disease model.

Kim KS, Kim HS, Park JM, Kim HW, Park MK, Lee HS, Lim DS, Lee TH, Chopp M, Moon J.

Neurobiol Aging. 2013 Oct;34(10):2408-20. doi: 10.1016/j.neurobiolaging.2013.03.029. Epub 2013 Apr 24.

PMID:
23623603
5.

Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis.

Melnikova T, Fromholt S, Kim H, Lee D, Xu G, Price A, Moore BD, Golde TE, Felsenstein KM, Savonenko A, Borchelt DR.

J Neurosci. 2013 Feb 27;33(9):3765-79. doi: 10.1523/JNEUROSCI.4251-12.2013.

6.
7.

Neuroendocrine immunomodulation network dysfunction in SAMP8 mice and PrP-hAβPPswe/PS1ΔE9 mice: potential mechanism underlying cognitive impairment.

Wang JH, Cheng XR, Zhang XR, Wang TX, Xu WJ, Li F, Liu F, Cheng JP, Bo XC, Wang SQ, Zhou WX, Zhang YX.

Oncotarget. 2016 Apr 26;7(17):22988-3005. doi: 10.18632/oncotarget.8453.

8.

Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice.

Cao D, Fukuchi K, Wan H, Kim H, Li L.

Neurobiol Aging. 2006 Nov;27(11):1632-43. Epub 2005 Oct 19.

PMID:
16236385
9.

A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model.

Hurtado DE, Molina-Porcel L, Iba M, Aboagye AK, Paul SM, Trojanowski JQ, Lee VM.

Am J Pathol. 2010 Oct;177(4):1977-88. doi: 10.2353/ajpath.2010.100346. Epub 2010 Aug 27.

10.

Role of Endoplasmic Reticulum Stress in Learning and Memory Impairment and Alzheimer's Disease-Like Neuropathology in the PS19 and APPSwe Mouse Models of Tauopathy and Amyloidosis.

Briggs DI, Defensor E, Memar Ardestani P, Yi B, Halpain M, Seabrook G, Shamloo M.

eNeuro. 2017 Jul 14;4(4). pii: ENEURO.0025-17.2017. doi: 10.1523/ENEURO.0025-17.2017. eCollection 2017 Jul-Aug.

11.

Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease.

Wang F, Gordon BA, Ryman DC, Ma S, Xiong C, Hassenstab J, Goate A, Fagan AM, Cairns NJ, Marcus DS, McDade E, Ringman JM, Graff-Radford NR, Ghetti B, Farlow MR, Sperling R, Salloway S, Schofield PR, Masters CL, Martins RN, Rossor MN, Jucker M, Danek A, Förster S, Lane CA, Morris JC, Benzinger TL, Bateman RJ; Dominantly Inherited Alzheimer Network.

Neurology. 2015 Sep 1;85(9):790-8. doi: 10.1212/WNL.0000000000001903. Epub 2015 Aug 5.

12.

Brain Amyloidosis and Triglycerides: Preventing Alzheimer Disease Pathology by Treating Vascular Disease?

Cohen AD, Aizenstein HJ.

Am J Geriatr Psychiatry. 2016 Aug;24(8):613-614. doi: 10.1016/j.jagp.2016.04.007. Epub 2016 Apr 27. No abstract available.

PMID:
27426209
13.

Cytosolic proteins lose solubility as amyloid deposits in a transgenic mouse model of Alzheimer-type amyloidosis.

Xu G, Stevens SM Jr, Moore BD, McClung S, Borchelt DR.

Hum Mol Genet. 2013 Jul 15;22(14):2765-74. doi: 10.1093/hmg/ddt121. Epub 2013 Mar 19.

14.

Methylene blue modulates β-secretase, reverses cerebral amyloidosis, and improves cognition in transgenic mice.

Mori T, Koyama N, Segawa T, Maeda M, Maruyama N, Kinoshita N, Hou H, Tan J, Town T.

J Biol Chem. 2014 Oct 31;289(44):30303-17. doi: 10.1074/jbc.M114.568212. Epub 2014 Aug 25.

15.

Cognitive and emotional alterations in App knock-in mouse models of Aβ amyloidosis.

Sakakibara Y, Sekiya M, Saito T, Saido TC, Iijima KM.

BMC Neurosci. 2018 Jul 28;19(1):46. doi: 10.1186/s12868-018-0446-8.

16.

Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities.

Parent MJ, Zimmer ER, Shin M, Kang MS, Fonov VS, Mathieu A, Aliaga A, Kostikov A, Do Carmo S, Dea D, Poirier J, Soucy JP, Gauthier S, Cuello AC, Rosa-Neto P.

J Neurosci. 2017 Dec 13;37(50):12263-12271. doi: 10.1523/JNEUROSCI.1346-17.2017. Epub 2017 Nov 2.

17.

Chronic treatments with a 5-HT4 receptor agonist decrease amyloid pathology in the entorhinal cortex and learning and memory deficits in the 5xFAD mouse model of Alzheimer's disease.

Baranger K, Giannoni P, Girard SD, Girot S, Gaven F, Stephan D, Migliorati M, Khrestchatisky M, Bockaert J, Marchetti-Gauthier E, Rivera S, Claeysen S, Roman FS.

Neuropharmacology. 2017 Nov;126:128-141. doi: 10.1016/j.neuropharm.2017.08.031. Epub 2017 Aug 26.

PMID:
28844596
18.
19.

GM-CSF upregulated in rheumatoid arthritis reverses cognitive impairment and amyloidosis in Alzheimer mice.

Boyd TD, Bennett SP, Mori T, Governatori N, Runfeldt M, Norden M, Padmanabhan J, Neame P, Wefes I, Sanchez-Ramos J, Arendash GW, Potter H.

J Alzheimers Dis. 2010;21(2):507-18. doi: 10.3233/JAD-2010-091471.

20.

Memory enhancement by Tamoxifen on amyloidosis mouse model.

Pandey D, Banerjee S, Basu M, Mishra N.

Horm Behav. 2016 Mar;79:70-3. doi: 10.1016/j.yhbeh.2015.09.004. Epub 2015 Oct 3.

PMID:
26435474

Supplemental Content

Support Center